About Stephanie de Beer, PhD

With a focus on pharmaceutical and life sciences patents, Stephanie de Beer serves as a technical advisor to the firm's Intellectual Property department in the New York office. A qualified attorney at law in The Netherlands before moving to the United States, Stephanie offers clients deep experience in complex, multijurisdictional patent litigation proceedings in Europe and the US involving pharmaceutical companies, including with regards to the Hatch-Waxman Act and abbreviated new drug applications in patent cases within the life sciences.

EU patent litigation insight for pharmaceutical and life sciences clients

Before the Dutch court, Stephanie has handled patent infringement disputes between originators and generic companies. This includes the validity assessment of patent claims in the context of European patent law and the relevant case law, as well as infringement analyses. She is experienced in the evaluation of the scientific background of the disputed subject matter of patents, especially regarding small molecules and complex macromolecular entities.

Stephanie's extended experience includes wider knowledge of civil, commercial and advertisement law and European regulatory issues. In this regard, she has worked with clients from various sectors such as the life sciences and consumer goods and services sectors. She advised pharmaceutical clients with regard to European market access strategies. She also assisted an international medical devices manufacturer regarding mass product liability claims.

Stephanie's predominant life sciences sector focus originates from her comprehensive academic career in the field of pharmaceutical chemistry. Her research resulted in several scientific publications and a PhD dissertation titled "Application of free energy calculations for drug design." Stephanie's dissertation offers an insight into the applicability and limitations of computational methods in the design of new (or improved) drugs by correlating computational data with experimental observations in both a qualitative and quantitative manner. She also collaborated with industrial partners on projects involving agricultural research and protein engineering on the drug-metabolizing Cytochrome P450 protein.

⇣   Expand to read more

Practice Focus

  • Intellectual property law
  • Patent litigation in the EU
  • Pharmaceutical and life sciences industries